HDAC inhibitors have been in clinical development as a single agent for hematopoietic malignancies such as myelodysplasia, a precursor of leukemia, and chronic myelomonocytic leukemia [12]. This evidence concerns the gene HDAC9 and chronic myelomonocytic leukemia.